Lokale Applikation von Mitoxantron beim inoperablen, stenosierenden Oesophaguskarzinom

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Am Beispiel zweier Krankheitsverläufe wird die Wirksamkeit der lokalen Applikation des Zytostatikums Mitoxantron bei inoperablen bzw. rezidivierten Ösophaguskarzinomen demonstriert. Die Verträglichkeit ist gut. Nebenwirkungen lokaler oder systemischer Art wurden bislang nicht beobachtet. Appliziert wurden bis zu 20 mg Mitoxantron multilokulär in die Tumorstenose mit dem Ösophagus-sklerosierungssystem. Bislang wurde dieses Verfahren bei fünf Patienten angewandt, und wir sahen in alien Fallen ein vorübergehendes subjektives und objektives Ansprechen.

Related collections

Author and article information

Journal

Journal ID (publisher-id): ONK

Journal ID (nlm-ta): Oncol Res Treat

Journal ID (doi): 10.1159/issn.2296-5270

Title: Oncology Research and Treatment

Publisher: S. Karger AG

ISSN (Print): 2296-5270

ISSN (Electronic): 2296-5262

Publication date Subscription-year: 1986

Publication date (Print): 1986

Publication date (Electronic): 24 April 2009

Volume: 9

Issue: 1

Pages: 27-29

Affiliations

^aRadiologische Klinik, Abt. Radioonkologie (Chefarzt: Prof. Dr. med. A. Düx), ^bChirurgische Klinik (Chefarzt Prof. Dr. med. G. Eßer), Krankenhaus Maria Hilf GmbH, Mönchengladbach

Article

Publisher ID: 215955 Other ID: Onkologie 1986;9:27–29

DOI: 10.1159/000215955

PubMed ID: 3523343

SO-VID: 9ba267ec-81c0-4b74-8035-951ff14787f0

License:

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

History

Page count

Pages: 3

Comments

Comment on this article

scite_

Cited by 1

Small molecule screen identifies pyrimethamine as an inhibitor of NRF2-driven esophageal hyperplasia
Authors: Chorlada Paiboonrungruang, Zhaohui Xiong, David Lamson …

See all cited by

Call for Papers: Beyond Biology: The Crucial Role of Sex and Gender in Oncology

Submit here before May 31, 2024